Delstrigo® (doravirine, lamivudine, and tenofovir disoproxil fumarate)
for Human Immunodeficiency Virus

Delstrigo is a once-daily HIV-1 treatment for adults and children weighing at least 35 kg. It combines doravirine (an NNRTI), lamivudine (an NRTI), and tenofovir (a nucleotide RTI) to stop the virus from multiplying. Delstrigo is used in patients with no prior HIV treatment or to replace a current regimen if certain conditions are met. It lowers HIV levels, helping the immune system work better and reducing the risk of HIV-related complications.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Human Immunodeficiency Virus - HIV